There are currently 2033 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC Norris Comprehensive Cancer Center, Children's Hospital Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Oral Nutritional Supplementation in Children at Risk of Undernutrition
NCT05161000
Recruiting
The objective of this randomized, controlled trial is to evaluate the effects of consuming a pediatric oral nutritional supplement (ONS) plus dietary counseling for 120 days on anthropometric growth, strength, and nutritional status, compared with dietary counseling alone in undernourished children in the United States.
Gender:
All
Ages:
Between 36 months and 107 months
Trial Updated:
01/22/2024
Locations: L.A. Universal Research Center, Inc., Los Angeles, California
Conditions: Undernutrition
Register for Updates
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
NCT04465487
Recruiting
There are two main goals of this study: The first is to find the highest safe dose of REGN6569 when given with cemiplimab. The second is to get some initial information about how well the REGN6569 in combination with cemiplimab may help shrink certain types of cancer. The study is also looking at: Side effects that may be experienced by people taking REGN6569 alone and with cemiplimab How REGN6569 and cemiplimab work in the body How much REGN6569 and cemiplimab is in your blood To see if REGN6... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: Angeles Clinic and Research Institute - Clinic/Outpatient Facility, Los Angeles, California
Conditions: Squamous Cell Carcinoma of Head and Neck
Register for Updates
EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome
NCT04462770
Recruiting
The purpose of this study is to evaluate the safety and efficacy of EPX-100 as adjunctive therapy in children and adult participants with Dravet Syndrome.
Gender:
All
Ages:
2 years and above
Trial Updated:
01/20/2024
Locations: Children's Hospital of Los Angeles, Los Angeles, California
Conditions: Dravet Syndrome
Register for Updates
The Family Perspectives Project Pilot Trial
NCT06039501
Recruiting
The purpose of the study is to conduct a pilot randomized trial of a program designed to enhance equitable communication and emotional support for families of critically ill patients in order to determine feasibility, acceptability, and participant experience with the program. The primary study procedures include: chart abstraction, questionnaires, meetings with ICU support counselors, meetings with ICU physicians and care team, audio recordings of these meetings (optional), and interviews with... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/19/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Respiratory Failure, Family Support, Physician-Patient Relations, Critical Illness
Register for Updates
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
NCT04572243
Recruiting
The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.
Gender:
All
Ages:
2 years and above
Trial Updated:
01/18/2024
Locations: University of California Los Angeles (UCLA), Los Angeles, California
Conditions: Epilepsies, Myoclonic
Register for Updates
Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
NCT03728985
Recruiting
Prospective, non-randomized, , multicenter study with two independent arms: Primary Study Arm - TAAA and Pararenal aneurysms requiring only TAMBE System. Hypothesis-driven analysis. Up to 65 additional subjects may be implanted in Continued Access Phase under the Primary Study Arm only Secondary Study Arm - TAAA requiring TAMBE System and CTAG Device(s). Non hypothesis-driven analysis. Minimum: 122 implanted subjects. Maximum: 202 implanted subjects with up to 65 additional subjects implanted... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
01/18/2024
Locations: Keck Medical Center of USC, Los Angeles, California +1 locations
Conditions: Thoracoabdominal Aortic Aneurysm
Register for Updates
Solve Together: A Data Collection Platform for the Collection of Patient and Control Health Information to Support Future Research That Will Accelerate Understanding of the Causes of and Possible Treatments for ME/CFS and Other Chronic Diseases, Including Post-viral Illnesses
NCT04806620
Recruiting
Solve Together is a platform designed to collect clinical data about post-infectious diseases, including ME/CFS and Long Covid. This data is made available to researchers and will be used to identify participants eligible for clinical studies. The platform also empowers patients to make reports for their doctors, connect medical records and/or a health-tracking wearable device, and identify their unique symptoms and health patterns.
Gender:
All
Ages:
All
Trial Updated:
01/18/2024
Locations: Solve ME/CFS Initiative, Los Angeles, California
Conditions: ME/CFS, Post-Acute COVID-19 Syndrome
Register for Updates
Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
NCT05306873
Recruiting
The primary purpose of this study is to evaluate the potential effectiveness of 24 weeks of MMF within previously discovered immunologically defined subsets of SLE patients. Treatment effects will be evaluated within the individual immunologically-homogenous subsets defined at screening. This study will also explore and compare pre-randomization gene expression patterns among responders and non-responders to MMF and MMF plus voclosporin, use comprehensive immunophenotyping to study the immunolog... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
01/18/2024
Locations: UCLA Medical Center: Division of Rheumatology, Los Angeles, California
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
NCT05399654
Recruiting
INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: University of Southern California (USC), Los Angeles, California
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)
NCT05523700
Recruiting
This study will evaluate the use of a mobile application in improving the patient-reported health outcome measures (PROMIS) for patients diagnosed with advanced stage ovarian, fallopian tube, and primary peritoneal cancer. The application will incorporate clinical data from the patient's medical chart as well as capture patient-reported outcome measures on an ongoing basis to better inform physicians and the care team so that necessary interventions may be implemented.
Gender:
Female
Ages:
Between 18 years and 90 years
Trial Updated:
01/18/2024
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Ovarian Cancer
Register for Updates
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
NCT04450173
Recruiting
This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ibrutinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab, ibrutinib, and venetoclax together may work better in tr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Register for Updates
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
NCT05694884
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Los Angeles, California
Conditions: Atopic Dermatitis
Register for Updates